EHR Reference Guides

The electronic health record (EHR) reference guides below are intended to help facilitate hepatitis B vaccination within your health system, in line with the Centers for Disease Control and Prevention (CDC) hepatitis B vaccination policy in adults.1,2

The following reference guides highlight decision support tools, chart functionalities, and population health strategies specific to Epic and Cerner software systems that can be leveraged to effectively implement hepatitis B vaccination in millions of adults who are now eligible for immunization.3

Epic Reference Guide for implementing the CDC adult hepatitis B vaccine policy.
Download for hepatitis B vaccination strategies that leverage Epic software decision support tools and functionalities.
Epic Reference Guide Click to download
Cerner Reference Guide for implementing the CDC adult hepatitis B vaccine policy.
Download for hepatitis B vaccination strategies that leverage Cerner software decision support tools and functionalities.
Cerner Reference Guide Click to download

References: 

  1. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483. 
  2. Murthy N, Wodi AP, Bernstein H, McNally V, Cineas S, Ault K. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:229-233.
  3. Data on file. Dynavax Technologies Corporation; 2022.

Important Safety Information

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast. 

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B. 

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B. 

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration. 

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%). 

Please see full Prescribing Information.